Results 71 to 80 of about 11,641 (246)

Combined activities of JNK1 and JNK2 in hepatocytes protect against toxic liver injury [PDF]

, 2015
Background & Aims: c-Jun N-terminal kinase (JNK)1 and JNK2 are expressed in hepatocytes and have overlapping and distinct functions. JNK proteins are activated, via phosphorylation, in response to acetaminophen- or CCl4-induced liver damage; the level of
Al Masaoudi, Malika, Bechmann, Lars P., Boekschoten, Mark V., Canbay, Ali E., Cubero, Francisco Javier, Davis, Roger J., Gassler, Nikolaus, Hu, Wei, Liedtke, Christian, Luedde, Tom, Muller, Michael, Nevzorova, Yulia A., Peng, Jin, Preisinger, Christian, Trautwein, Christian, Zhao, Gang, Zoubek, Miguel Eugenio   +16 more
core   +1 more source

Clinical Characteristics of Patients with Drug-induced Liver Injury

Chinese Medical Journal, 2017
Background: Drug is an important cause of liver injury and accounts for up to 40% of instances of fulminant hepatic failure. Drug-induced liver injury (DILI) is increasing while the diagnosis becomes more difficult.
Li-Xia Yang, Cheng-Yuan Liu, Lun-Li Zhang, Ling-Ling Lai, Ming Fang, Chong Zhang   +5 more
doaj   +1 more source

Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury [PDF]

, 2015
Drug-induced liver injury (DILI) is a major concern for public health, as well as for drug development in the pharmaceutical industry, since it can cause liver failure and lead to drug withdrawal from the market and black box warnings.
Kim, Seung-Hyun, Naisbitt, Dean J
core   +1 more source

Late-onset isavuconazole-induced liver injury

Medical Mycology Case Reports, 2018
Antifungal agents account for approximately 3% of Drug-Induced Liver Injury (DILI) cases. Isavuconazole is a novel triazole, and experience with long-term use of it is lacking.
Felix Bongomin, Isabel Rodriguez-Goncer, Carol Lorden, Akaninyene Otu, Rohit Bazaz   +4 more
doaj   +1 more source

The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury

Frontiers in Pharmacology, 2021
Drug-induced liver injury (DILI) has become one of the major challenges of drug safety all over the word. So far, about 1,100 commonly used drugs including the medications used regularly, herbal and/or dietary supplements, have been reported to induce ...
Wenhui Liu, Wenhui Liu, Wenhui Liu, Wenhui Liu, Xiangchang Zeng, Xiangchang Zeng, Xiangchang Zeng, Xiangchang Zeng, Yating Liu, Yating Liu, Yating Liu, Yating Liu, Jinfeng Liu, Jinfeng Liu, Jinfeng Liu, Jinfeng Liu, Chaopeng Li, Lulu Chen, Hongying Chen, Hongying Chen, Hongying Chen, Hongying Chen, Dongsheng Ouyang, Dongsheng Ouyang, Dongsheng Ouyang, Dongsheng Ouyang, Dongsheng Ouyang   +26 more
doaj   +1 more source

Amoxicillin-Clavulanate-Induced Liver Injury [PDF]

, 2016
Background and Aims Amoxicillin–clavulanate (AC) is the most frequent cause of idiosyncratic drug-induced injury (DILI) in the US DILI Network (DILIN) registry.
Andrew S. deLemos, David E. Kleiner, Don C. Rockey, Herbert L. Bonkovsky, Huiman X. Barnhart, Jiezhun Gu, Marwan Ghabril, null null, Robert J. Fontana   +8 more
core   +1 more source

A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury [PDF]

, 2019
BACKGROUND & AIMS: We performed genetic analyses of a multiethnic cohort of patients with idiosyncratic drug-induced liver injury (DILI) to identify variants associated with susceptibility.
Cirulli, Elizabeth T., Drug-Induced Liver Injury Network, Int DILI Consortium iDILIC, Laitinen, Tarja, Nicoletti, Paola   +4 more
core   +1 more source

A gene expression profile-based approach to screen the occurrence and predisposed host characteristics of drug-induced liver injury: a case study of Psoralea corylifolia Linn

Frontiers in Chemistry, 2023
Drug-induced liver injury (DILI) is one of the most common causes of a drug being withdrawn, and identifying the culprit drugs and the host factors at risk of causing DILI has become a current challenge. Recent studies have found that immune status plays
Ming-Liang Zhang, Ming-Liang Zhang, Ming-Liang Zhang, Ming-Liang Zhang, Wei-Xia Li, Wei-Xia Li, Wei-Xia Li, Wei-Xia Li, Xiao-Yan Wang, Xiao-Yan Wang, Xiao-Yan Wang, Xiao-Yan Wang, Hui Zhang, Hui Zhang, Hui Zhang, Hui Zhang, Ya-Li Wu, Ya-Li Wu, Ya-Li Wu, Ya-Li Wu, Liu-Qing Yang, Liu-Qing Yang, Liu-Qing Yang, Liu-Qing Yang, Xiao-Fei Chen, Xiao-Fei Chen, Xiao-Fei Chen, Xiao-Fei Chen, Shu-Qi Zhang, Shu-Qi Zhang, Shu-Qi Zhang, Shu-Qi Zhang, Yu-Long Chen, Ke-Ran Feng, Ke-Ran Feng, Ke-Ran Feng, Ke-Ran Feng, Jin-Fa Tang, Jin-Fa Tang, Jin-Fa Tang, Jin-Fa Tang, Jin-Fa Tang   +41 more
doaj   +1 more source

Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: a study in three European data sources [PDF]

, 2019
This is the peer reviewed version of the following article: Forns, J. [et al.]. Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: a study in three European data sources. "Pharmacoepidemiology and drug safety", 6 Juny 2019, vol.
Cainzos Achirica, Miguel, Castellsagué, Jordi, Cortés Martínez, Jordi, Deltour, Nicole, Forns, Joan, Giner Soriano, Maria, Hallas, Jesper, Hellfritzsch, M, Jacquot, Emmanuelle, Morros Padrós, Rosa, Pladevall, Miquel, Poblador Plou, Beatriz, Pottegard, Anton, Prados Torres, Alexandra, Pérez Gutthann, Susana   +14 more
core   +5 more sources

A Complex Case of Cholestasis in a Patient with ABCB4 and ABCB11 Mutations [PDF]

, 2018
The low-phospholipid-associated cholelithiasis (LPAC) syndrome is a form of symptomatic cholelithiasis occurring in young adults, characterized by recurrence of symptoms after cholecystectomy and presence of hepatolithiasis.
Anapaz, V, Branco, J, Cardoso, M, Carvalho, R, Horta, D, Martins, A, Reis, J, Rodrigues, C   +7 more
core   +1 more source